Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of orelabrutinib in primary central nervous system lymphoma
ChiCTR2100047954Phase 2Not yet recruiting
- Sponsor
- Second Hospital of Lanzhou University
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of orelabrutinib in primary central nervous system lymphoma (PCNSL) (3 arms), sponsored by Second Hospital of Lanzhou University. Primary endpoint: Objective response rate. Planned start Jul 2021; status: not yet recruiting.
02
Drugs
orelabrutinib
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on ChiCTR2100047954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100047954.